Exelixis
EXEL
146 hedge funds and large institutions have $983M invested in Exelixis in 2015 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 34 reducing their positions, and 23 closing their positions.
134% more call options, than puts
Call options by funds: $16M | Put options by funds: $6.86M
53% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 34
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
10% more capital invested
Capital invested by funds: $892M → $983M (+$91.5M)
7% more funds holding
Funds holding: 136 → 146 (+10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$39.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$12.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.2M |
| 4 |
AC
Armistice Capital
New York
|
+$7.11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.41M |
Top Sellers
EXEL Hedge Fund Activity: Q4 2015 in Review
146 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Exelixis (EXEL) for Q4 2015, worth a combined $983M — up 10% from $892M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EXEL positions and 23 closed out — a net gain of 10 holders — while 52 added to existing stakes and 34 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $39.7M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $8.88M sold.
- 146 institutional investors held Exelixis (EXEL) as of Q4 2015, up from 136 in Q3 2015.
- Funds reported $983M of Exelixis stock for Q4 2015, up 10% quarter-over-quarter.
- 33 funds opened new Exelixis positions in Q4 2015 and 23 closed out, a net change of +10 holders.
- The largest Exelixis buyer in Q4 2015 was Citadel Advisors, an estimated $39.7M added.
- The largest Exelixis seller in Q4 2015 was Bogle Investment Management, an estimated $8.88M sold.
Based on aggregated 13F filings for Q4 2015.